Cure­Vac to de­vel­op mR­NA-based flu, malar­ia vac­cines with new Gates Foun­da­tion grants

With a fresh round of fund­ing from the Bill and Melin­da Gates Foun­da­tion, Cure­Vac is gear­ing up its mes­sen­ger RNA plat­form to de­vel­op mR­NA-based vac­cines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.